Radiolabeled antibody cytotoxic therapy of cancer
US5120525A · kind A · utility
57Cited by
9References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Dec 5, 1990 |
| Grant date | Jun 9, 1992 |
| Priority date | — |
| Expiry date | Dec 5, 2010 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2121/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Anticancer, antimicrobial and autoimmune disease, and anti-organ rejection therapy using cytotoxic agents is improved using cytokines to prevent, mitigate or reverse adverse radiation-induced or drug-induced toxicity, especially to hemotopoietic cells. Cytotoxic agents can include radioisotopes, drugs, toxins and even unconjugated cytotoxic antibodies. A preferred cytokine is IL-1. Higher doses of cytotoxic agents can be administered and tolerated by the patient and dose-limiting marrow toxicity can be prevented, palliated or reversed using adjunct cytokine therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.